Keymed-B (02162) rose against the market trend by over 3%. As of the time of writing, it increased by 3.14%, trading at HKD 64.25, with a turnover of HKD 49.0222 million.
According to Zhitong Finance, Connaught Medical-B (02162) rose over 3% against the market trend. As of press time, it increased by 3.14%, trading at HKD 64.25, with a transaction volume of HKD 49.0222 million.
In terms of news, according to an official update from Connaught Medical-B, on November 4, the company announced that CM512, its self-developed world-first long-acting TSLP x IL-13 dual blocker for treating adult moderate-to-severe atopic dermatitis (AD), achieved all endpoints in its Phase I clinical trial. The study demonstrated that CM512 exhibits rapid disease control capabilities in treating moderate-to-severe atopic dermatitis patients, showing deep remission and sustained efficacy with a half-life of up to 70 days, coupled with favorable safety profiles, preliminarily reflecting its best-in-class therapeutic potential for adult moderate-to-severe atopic dermatitis.
CM512 is the world’s first self-developed IgG-like long-acting TSLP x IL-13 dual blocker by Connaught Medical. It simultaneously targets TSLP and IL-13, enabling early inhibition of inflammatory cascade initiation, effectively reducing Th2 cell differentiation and cytokine release such as IL-13, while directly suppressing pathological symptoms driven by IL-13, thereby offering more effective treatment for type 2 inflammation-related diseases. Currently, Connaught Medical is rapidly advancing Phase II clinical trials of CM512 for indications including atopic dermatitis, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.